We are a leader in the development and sale of innovative, broadly enabling, pressure-based platform solutions for the worldwide life sciences industry. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus has been in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology platform) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be acceptably preserved using existing non-thermal technologies.
Company profile
Ticker
PBIO
Exchange
Website
CEO
Richard T. Schumacher
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BOSTON BIOMEDICA INC
SEC CIK
Corporate docs
Subsidiaries
WHEREAS, the Company • “Closing Date” means the date on which the Company • “Common Stock” means the common stock of the Company • “Person” means an individual or corporation, partnership • “Preferred Stock” means the Series CC Convertible Preferred Stock of the Company • 2.1 Articles of Amendment. On or before the Closing, the Company • (b) On or prior to the Closing (or following the closing, if agreed to between Company • (a) The obligations of the Company • (ii) all obligations, covenants and agreements of the Company • (iii) the delivery by the Company ...
IRS number
42652826
PBIO stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
22 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
DEF 14A
Definitive proxy
27 Feb 24
8-K
Entry into a Material Definitive Agreement
25 Jan 24
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Departure of Directors or Certain Officers
23 Oct 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
Transcripts
PBIO
Earnings call transcript
2023 Q3
21 Nov 23
PBIO
Earnings call transcript
2023 Q2
22 Aug 23
PBIO
Earnings call transcript
2023 Q1
16 May 23
PBIO
Earnings call transcript
2022 Q4
18 Apr 23
PBIO
Earnings call transcript
2022 Q3
22 Nov 22
PBIO
Earnings call transcript
2022 Q2
18 Aug 22
PBIO
Earnings call transcript
2022 Q1
19 May 22
PBIO
Earnings call transcript
2021 Q4
5 Apr 22
PBIO
Earnings call transcript
2021 Q3
17 Nov 21
PBIO
Earnings call transcript
2021 Q2
19 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.26 k | 5.26 k | 5.26 k | 5.26 k | 5.26 k | 5.26 k |
Cash burn (monthly) | 6.57 k | 18.80 k | 430.94 k | 629.92 k | 244.15 k | 290.05 k |
Cash used (since last report) | 49.23 k | 140.87 k | 3.23 mm | 4.72 mm | 1.83 mm | 2.17 mm |
Cash remaining | -43.97 k | -135.60 k | -3.22 mm | -4.71 mm | -1.82 mm | -2.17 mm |
Runway (months of cash) | -6.7 | -7.2 | -7.5 | -7.5 | -7.5 | -7.5 |
Institutional ownership, Q1 2023
1.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 8.45 mm |
Total shares | 421.02 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
LG Capital Funding | 415.01 k | $950.00 k |
Archer Investment | 6.00 k | $7.50 mm |
Eagle Equities | 10.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Urdea Michael S | Common Stock | Other | Acquire J | No | No | 0.16 | 2,872 | 459.52 | 33,159 |
27 Mar 24 | Schumacher Richard T | Common Stock | Other | Acquire J | No | No | 0.16 | 4,554 | 728.64 | 60,089 |
27 Mar 24 | Pollack Kevin | Common Stock | Other | Acquire J | No | No | 0.16 | 2,914 | 466.24 | 36,787 |
27 Mar 24 | Peterson Jeffrey N | COMMON STOCK | Other | Acquire J | No | No | 0.16 | 11,874 | 1.90 k | 82,432 |
27 Mar 24 | Mangiardi Vito J | COMMON STOCK | Other | Acquire J | No | No | 0.16 | 625 | 100.00 | 16,104 |
Press releases
Uncle Bud's Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness
11 Apr 24
Pressure BioSciences' Uncle Bud's Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New "Premium Collection"
2 Apr 24
Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.
26 Feb 24
Pressure BioSciences Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing
15 Feb 24